Breaking News: Myriad Genetics Acquires Gateway Genomics | Learn More
Visit us at booth #1001
Provide your contact information below and we’ll send you all four of our SABCS 2022 poster presentations directly to your inbox after the conference.
Contact Information
Every day, cancer care is evolving. That means your work as a clinician is always changing, and your day is never done. That’s why we’re evolving to better support your care for breast cancer patients.
Day in and day out, as cancer care keeps advancing, so will we.
Treating cancer is complex, but your testing experience doesn’t need to be. Precise Oncology Solutions provides a streamlined testing experience.
Learn more about Precise Oncology Solutions
Guidelines agree, the OlympiA trial identified important frontline options for high-risk patients with breast cancer.
Download the OlympiA Clinical Summary
Every patient deserves an answer. Now you can provide one. Germline testing with Myriad Genetics will provide results for every breast cancer patient.
Learn more about germline testing
Hear how Dr. Sharyn Lewin uses germline testing in conjunction with somatic testing to help guide treatment decisions.
Poster Title: Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women
Session Date / Time: Spotlight Poster Discussion 14 Thursday, December 8 Poster Session #2 5:00-6:15 PM Poster ID: PD14-05
Location: Stars at Night Ballroom 3&4
Poster Title: I: Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry
Session Date / Time: Poster Session #2 Wednesday, December 7 7:00-8:15 AM Poster ID: P2-03-23
Location: Hall 1
Poster Title: Variant Classification Discordance: A real-world experience of genetic test results in a community-based setting
Session Date / Time: Poster Session #5 Thursday, December 8 5:00-6:16 PM Poster ID: P2-03-03
Poster Title: Long-term outcome data using EndoPredict® as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer
Session Date / Time: Poster Session #6 Friday, December 9 7:00-8:15 AM Poster ID: P6-01-24
Poster Title: Neoadjuvant hormonal therapy plus Palbociclib versus hormonal therapy plus placebo in women with operable, hormone sensitive and HER2-negative primary breast cancer
Session Date / Time: Poster session #5 Thursday, December 8 07:00 – 08:15 AM CST Poster ID: P5-09-01 (pdf PALBOCICLIB)
To request reflex testing for patients who test negative for BRCA1/2 mutations, simply check the box for Myriad Genetics MyRisk™ Hereditary Cancer Test on the test request form. This will provide an analysis of additional germline cancer genes for patients who have been testing with BRACAnalysis CDx.
BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein-coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.
Results of the test are used as an aid in identifying patients who are or may become eligible for treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling.
Detection of deleterious or suspected deleterious germline BRCA1 and BRCA2 mutations by BRACAnalysis CDx test in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula® (niraparib) or Rubraca® (rucaparib) maintenance therapy.
This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory site located at 320 Wakara Way, Salt Lake City, UT 84108
Limitation: in ovarian cancer, ~70% of tumor BRCA1 and BRCA2 mutation positive patients are estimated to have a germline mutation while ~30% of patients are estimated to have a somatic mutation. The BRACAnalysis CDx test detects germline mutations only, not somatic mutations from a patient’s blood sample. A negative result using the BRACAnalysis CDx blood test in ovarian cancer patients does not rule out the possibility of a somatic BRCA1 and BRCA2 mutation in tumor tissue from these patients.
Limitation: in prostate cancer, ~50% of tumor BRCA1 and BRCA2 mutation positive patients are estimated to have a germline mutation while ~50% of patients are estimated to have a somatic mutation. The BRACAnalysis CDx test detects germline mutations only, not somatic mutations from patient’s blood sample. A negative result using the BRACAnalysis CDx blood test in prostate cancer patients does not rule out the possibility of a somatic BRCA1 and BRCA2 mutation in tumor tissue from these patients.
LYNPARZA is a registered trademark of the AstraZeneca group of companies.